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A B S T R A C T
Introduction: The aim of this study was to evaluate the incidence of toxoplasmosis infection during
pregnancy and to describe the characteristics of the serological status, management, follow-up and
treatment.
Material and methods: This is a population-based cohort study of women referred for suspected
toxoplasmosis during pregnancy from January, 2001 to December, 2012. Suspected toxoplasmosis was
deﬁned as positive IgM antibody during pregnancy. Women with suspected toxoplasmosis during
pregnancy were classiﬁed into three groups: seroconversion, suspected infection, or no infection in
pregnancy. Women in the ﬁrst and second group were treated according to local protocol, and
amniocentesis with toxoplasmosis PCR detection and serial detailed ultrasound scans were offered.
Neonates were investigated for congenital toxoplasmosis at birth and were monitored for at least one
year after birth.
Results: During the study period, there were 738,588 deliveries in Campania. Of them 1159 (0.2%) were
referred to our Institution for suspected toxoplasmosis during pregnancy: 183 (15.8%) women were
classiﬁed as seroconversion, 381 (32.9%) were suspected infection, and 595 (51.3%) were not infected in
pregnancy. Neonatal outcome was available for 476 pregnancies, including 479 neonates (3 twins, 473
singletons), out of the 564 pregnancies with seroconversion or suspected infection. 384 (80.2%) babies
were not infected at birth and at follow-up, 67 (14.0%) had congenital toxoplasmosis, 10 (2.1%) were
voluntary induced termination of pregnancy, 15 (3.1%) were spontaneous miscarriage, and 4 (0.8%) were
stillbirth (of which one counted already in the infected cohort). Considering cases of congenital
toxoplasmosis, the transmission rate in women with seroconversion was 32.9% (52/158), and in women
with suspected infection was 4.7% (15/321).
Conclusions: Toxoplasmosis is uncommon in pregnancy with overall incidence of seroconversion and
suspected infection in pregnancy of 0.8 per 1000 live births and incidence of congenital toxoplasmosis 0.1
per 1000 live births when applying a strict protocol of screening, follow-up, and treatment. 51.3% (595/
1159) of women referred to our center for suspected infection were actually considered not infected.
© 2019 Published by Elsevier B.V.
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Toxoplasmosis is one of the common worldwide parasitic
zoonosis caused by the intracellular protozoon Toxoplasma
gondii. Maternal primary infection may cause congenital
toxoplasmosis when acquired during pregnancy, because of
the transplacental passage of the parasite [1]. The infection in
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restriction, ocular and central nervous system abnormalities
with auditory and visual disorders, and mental retardation in
the infant [1,2].Vertical transmission increases with gestational
age, while the severity of the symptoms in the fetus are
inversely related [3].
Diagnosis of maternal infection almost completely relies on
serological ﬁndings including IgM, IgG, and IgG Avidity. Serocon-
version is demonstrated when IgM and IgG from negative become
positive with both samples taken after conception [4].
The seroprevalence of the infection in women in childbearing
age in Italy is considered to have deceased over the last 30 years. It
was estimated 48.5% in the 1991 [5], 21.5% in the 2005 [6] and,
recently, 22.3% in the 2011 [7]. On the other hand the risk of
congenital toxoplasmosis in case of maternal infection can be as
high as 70% in the third trimester [3], therefore the effectiveness of
a policy of universal screening for toxoplasmosis infection during
pregnancy is still subject of debate [8].
Objective
The aim of this study was to evaluate the incidence of
toxoplasmosis infection during pregnancy in a population-based
cohort study, and to describe the characteristics of the serological
status, management, follow-up and treatment.
Material and methods
Study design
This is a population-based cohort study of women counselled
for suspected toxoplasmosis infection during pregnancy between
January, 2001 and December, 2012 in Campania, Italy.
In Italy, all pregnant women are screened for toxoplasmosis
during pregnancy with IgG and IgM antibody at the ﬁrst visit and, if
both negative, every month until delivery. In Campania, Italy, all
women who were found to have positive IgM antibody are referred
for counselling and further evaluation at University of Naples
Federico II, Naples, Italy.
At the ﬁrst counselling visit, women undergo samples for IgG
and IgM antibodies and IgG avidity at our reference laboratory at
University of Naples Federico II, analyzed by enzyme immuno-
assays (EIAS). The results were expressed in international units per
ml (IU/ml). IgM antibodies were considerate as negative if <0.55,
borderline if included between 0.55 and 0.65, and positive if >0.65.
IgG antibodies were considered as negative if <4, borderline if
included between 4 and 8, and positive if >8. IgG avidity was
considered as low if <0.200, intermediate if between 0.200 and
0.300, and high if >0.300.
Women were therefore classiﬁed into three groups according to
antibody status:
1 Group 1: Seroconversion.
One or more samples taken with IgG-/IgM- followed by another
sample with IgG+/IgM+. The time of seroconversion (ﬁrst, second,
or third trimester) was calculated as the midpoint between the last
IgG-/IgM-, and ﬁrst IgM+/IgG + test or 14 days before the ﬁrst
IgM + if IgG- test [3].
2 Group 2: Suspected infection:
IgG+/IgM + at ﬁrst sample taken in pregnancy. This subset of
women was further classiﬁed according to the IgG avidity results
(low, intermediate, and high avidity). Women with IgG+/IgM + at
ﬁrst sample taken in pregnancy but with high avidity before 12weeks were excluded from this group and were classiﬁed in
Group 3.
3 Group 3: No infection in pregnancy:
Susceptible: IgG-/IgM-
Past infection: IgG+/IgM- and/or maternal preconception
seropositive sample
Persistent IgM antibodies: IgM + without appearance of IgG
IgG+/IgM + at ﬁrst sample taken in pregnancy with high avidity
before 12 weeks
Maternal management and follow-up
Women in group 3 were discharged from follow-up.
Women in the ﬁrst and second group were treated according to
a local protocol. Amniocentesis for the presence of Toxoplasma
DNA by polymerase chain reaction (PCR) was offered starting from
20 0/7 weeks and until 23 6/7 weeks of gestation, at least after 6
weeks following seroconversion in case of group 1 woman, and in
selected cases in case of group 2. Women were also offered detailed
ultrasound scan every 4 weeks after routine anatomy scan, in order
to look for ultrasound signs suggestive of fetal infection (i.e. fetal
abnormalities including ventriculomegaly, brain or hepatic calci-
ﬁcations, cataract, hepatosplenomegaly, ascites, severe IUGR) [9].
Local protocol included:
- Amniocentesis positive regardless of the group: pyrimethamine
(50 mg every 12 h for 2 days, then 50 mg daily) with sulfadiazine
(75 mg/kg followed by 50 mg/kg every 12 h, respecting a maximum
of 4 g/day), and folinic acid (10–20 mg daily) until 38 weeks.
- Amniocentesis negative regardless of the group: Spiramycin
3000 IU every 8 h until delivery.
- Amniocentesis not performed: Spiramycin 3000 IU every 8 h
until delivery in case of group 2 women; pyrimethamine (50 mg
every 12 h for 2 days, then 50 mg daily) with sulfadiazine
(75 mg/kg followed by 50 mg/kg every 12 h, respecting a
maximum of 4 g/day), and folinic acid (10–20 mg daily) from
22 weeks until 38 weeks, in case of group 1 women.
- Ultrasound signs of infection regardless of the group and
regardless of the amniocentesis result: pyrimethamine (50 mg
every 12 h for 2 days, then 50 mg daily) with sulfadiazine
(75 mg/kg followed by 50 mg/kg every 12 h, respecting a
maximum of 4 g/day), and folinic acid (10–20 mg daily) until
38 weeks.
Neonatal management and follow-up
All babies born from women in group 1 and 2 were followed by
a team of selected pediatricians. The protocol for neonatal and
children surveillance offered in our center has already been
described in a previous report [10]. In summary, babies were
considered infected in case of presence of IgG antibodies beyond
age 12 months without speciﬁc treatment.
Statistical analysis
Statistical analysis was performed using Statistical Package for
Social Sciences (SPSS) v. 19.0 (IBM Inc., Armonk, NY, USA).
Data are shown as means, or as number (percentage).
Univariate comparisons of dichotomous data were performed
with the use of the chi-square test with continuity correction.
Comparisons between groups were performed with the use of the
t-test to test group means by assuming equal within-group
variances. Odds ratio (OR) with 95% conﬁdence interval (CI) was
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signiﬁcant.
Positive and negative likelihood ratio and sensibility and
speciﬁcity of ultrasound and amniocentesis were also calculated
This study was reported following the Strengthening The
Reporting of Observational studies in Epidemiology guidelines [11].
Results
Population characteristics
During the study period, there were 738,588 deliveries in
Campania. Of them 1159 (0.2%) were referred to University of
Naples for suspected toxoplasmosis during pregnancy, deﬁned as
positive IgM antibody during pregnancy. After conﬁrmed sample in
our reference laboratory, 183 (15.8%) women were classiﬁed as
seroconversions, 381 (32.9%) were suspected infection and 595
(51.3%) were not infected in pregnancy (Fig. 1).
Out of the 183 women with seroconversion, 79 (43.2%) were
ﬁrst-trimester seroconversion, 88 (48.1%) second-trimester, and 16Fig. 1. Study ﬂ(8.7%) third-trimester. Out of the 381 women classiﬁed in the
Group 2: 220 (57.7%) had low avidity, 161 (42.3%) had intermediate
avidity or high avidity after 12 weeks.
Finally, out of the 595 women classiﬁed in group 3: 18 (3.0%)
were susceptible, 120 (20.2%) were past infection, 27 (4.5%) were
persistent IgM, and 430 (72.3%) were high avidity before 12 weeks.
51.3% (595/1159) of women (Group 3) referred to our center for
suspected infection were therefore considered as not infected in
pregnancy after analysis of serology in previous pregnancies, when
available, and conﬁrmed sample in our reference laboratory, and
were therefore discharged with no further follow-up.
In the remaining 564 women (Group 1 and Group 2),
amniocentesis was performed in 256 (45.4%) cases. 47 (18.4%)
cases were positive.
Management and follow-up
All women in group 1 and 2 received treatment during
pregnancy. 75% (423/564) of the women received prophylaxis
with spiramycin, 3.5% (20/564) received treatment withow chart.
Table 1
Characteristics of pregnancies ended with adverse outcome including voluntary termination of pregnancy (VTP), miscarriage, and stillbirth.
Total Group Amnio positive/
tot amnio
Ultrasound sign present/ tot ultrasound
VTP 10 3 (30)
7 (70)
Group 1
Group 2
3 seroconversion I trim 0 0/11
Miscarriage 15 2
(13.3)
13
(86.7)
Group 1
Group 2
2 seroconversion I trim 1/2 (50%) 0/16
Stillbirth 4 3 (75) Group 1 1 seroconversion I trim, 1 seroconversion II trim, 1
seroconversion III trim
1/2 (50%) 1/4 (25%) brain and hepatic calciﬁcations,
hepatosplenomegaly, ventriculomegaly
1 (25) Group 2
Table 2
Ultrasound signs suggestive of congenital toxoplasmosis in infected and not infected fetuses.
Infected Not infected Tot P value OR (CI)
67 (16.5) 384 (83.5) 451
At least one US sign 7 (10.4) 6 (1.6) 13 0.001 7.4 (2.4 to 22.6)
Brain calciﬁcation 3 (4.5) 0 (0) 3 (0.7) 0.003
Ventriculomegaly 4 (6) 3 (0.8) 7 (1.6) 0.011 8.1 (1.8 to 38.9)
Cataract 0 1 (0.3) 1 (0.2) 0.851
hepatosplenomegaly 2 (3) 0 2 (0.4) 0.022
Ascites 1 (1.5) 0 1 (0.2) 0.149
Hepatic calciﬁcation 2 (3) 0 2 (0.4) 0.022
IUGR 2 (3) 2 (0.5) 4 (0.9) 0.107 5.1 (0.8 to 42.5)
IUGR, intrauterine growth restriction; US, ultrasound; OR, odds ratio; CI, conﬁdence interval.
Data presented as number (percentage).
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spiramycin followed by pyrimethamine and sulfadiazine, and one
patient refused the treatment at all because intended to terminate
the pregnancy.
Ultrasound follow-up was performed in all 183 women of group
1 and those 381 of group 2 (Fig. 1). The most common ultrasound
sign suggestive of congenital toxoplasmosis was ventriculomegaly,
present in 4 (2.2%) fetuses of group 1 and in 3 (0.8%) of group 2.
Neonatal outcomes
Neonatal outcome was available for 476 pregnancies, including
479 neonates (3 twins, 473 singletons), out of the 564 pregnancies
with seroconversion or suspected infection. 384 (80.2%) babies
were not infected at birth and at follow-up, 67 (14.0%) had
congenital toxoplasmosis, 10 (2.1%) were voluntary induced
termination of pregnancy, 15 (3.1%) were spontaneous miscarriage,
and 4 (0.8%) were stillbirth (of which one counted already in the
infected cohort).
Pregnancies with adverse outcome
Characteristics of pregnancies ended with adverse outcome,
including voluntary termination of pregnancy, miscarriage and still
birth are shown in Table 1. Ultrasound signs suggestive of
congenital toxoplasmosis in infected and not infected fetuses
are shown in Table 2.
10.4% of the fetuses with of congenital toxoplasmosis had at
least one ultrasound sign suggestive of infection compared with
1.6% not infected fetuses (p value 0.001, OR 7.4, CI 2.4 to 22.6).
Fetuses with congenital toxoplasmosis had statistically signiﬁcant
higher risk of having brain calciﬁcation, ventriculomegaly,
hepatosplenomegaly, hepatic calciﬁcation compared to not
infected fetuses (Table 2).Sensitivity and speciﬁcity of ultrasound and of amniocentesis
Overall positive and negative likelihood ratio of ultrasound
were respectively 5.7 (95% CI 1.9 to 17.2) and 0.9 (95% CI 0.9 to 1),
sensitivity was 9% and speciﬁcity was 98.4%. Furthermore, positive
and negative likelihood ratio of amniocentesis were respectively
11.9 (95% CI 7 to 10.1) and 0.2 (95% CI 0.1 to 1.4), sensitivity was
86.2% and speciﬁcity was 92.8%.
Prevalence of toxoplasmosis
Considering cases of congenital toxoplasmosis, 52 children
were born from women in group 1 resulting in a transmission rate
of 32.9%; 17.6% (12/68) of children had congenital toxoplasmosis in
case of seroconversion in the ﬁrst trimester, 40.5% (32/79) in the
second trimester and 53.3% (8/15) in the third trimester. The
remaining 15 children were born from women in group 2 with a
transmission rate of 4.7%.
Considering the 738,588 deliveries in Campania from January
2001 to December 2012, the overall incidence of seroconversion and
suspected infection in pregnancy was 0.8 per 1000 live births and
incidence of congenital toxoplasmosis was 0.1 per 1000 live births.
Discussion
Main ﬁndings
Our study showed that 51.3% (595/1159) of women referred for
suspected toxoplasmosis during pregnancy were considered not
infected after analysis of serology in previous pregnancies, and
conﬁrmatory test at reference laboratory. These data highlighted
the importance to standardize techniques and tests for toxoplas-
mosis in the laboratories, and also the need to refer these cases to
centralized centres where there are trained doctors in this speciﬁc
ﬁeld for further evaluation and counselling. The reason for this is
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maternal infection in pregnancy is uncertain, is difﬁcult to quantify
the risk of fetal adverse outcome. This may lead to unnecessary
tests, and couple anxiety associated with uncertainty on baby’s
prognosis that can induce unnecessary interventions including
termination of pregnancy [12,13].
Nowadays the ability to identify toxoplasmosis infection is
primarily based on serological assay (detection of IgM, IgG, and IgG
avidity). Consistently presence of IgM antibodies are a transient
marker of recent acute infection, however they may persist for a
longer period of time [14]. On the other hand the high avidity test
can help conﬁrm chronic infections, but low or intermediate levels
do not conﬁrm a recent infection because they can persist for a
longer time [14–17].
In our cohort we identiﬁed 183 women with documented
seroconversion in pregnancy and 381 women with suspected
infection in pregnancy due to presence of both IgM and IgG and low
or intermediate avidity or high avidity after 12 weeks.
Ultrasound follow up was extensively performed in all these
pregnancies, but signs of infection were uncommon. Only 7 (10.4%)
fetuses with congenital toxoplasmosis had at least one ultrasound
sign suggestive of infection. Manderlbrot et al. documented similar
result, they reported only cerebral ultrasound signs of infection
which were present in 4.2% of fetuses with congenital toxoplas-
mosis [18]. In our cohort when ultrasound signs of infection were
detected, 57.1% of women were undergoing treatment with
spiramycin and 42.9% with pyrimethamine and sulfadiazine.
256 amniocentesis were performed, with sensitivity of 86.2%
and speciﬁcity of 92.8%. In other studies was reported a higher
sensitivity and speciﬁcity close to 100% [19,20]. This discordance in
the result could be explained by worst quality control in laboratory
performance, a reduction of parasite load due to maternal
treatment or delayed in transmission.
The rate of transmission was overall 32.9% (52/158) in women
with documented seroconversion in pregnancy. The rate of
congenital toxoplasmosis increased comparing the trimester of
seroconversion, according to literature [3], subdivided as: 17.6%
(12/68) of children had congenital toxoplasmosis in case of
seroconversion in the ﬁrst trimester, 40.5% (32/79) in the second
trimester and 53.3% (8/15) in the third. The remaining 15 children
were born from women with suspected infection in pregnancy
with a transmission rate of 4.7%. Rate of congenital toxoplasmosis
in women with suspected infection has been recently docu-
mented to be as high as 56% by Avelino et at. [21], and much lower
as 0.8–4.8% in other studies in women with IgM+/IgG + and low
avidity [22,23]. This wide difference in rate of congenital
toxoplasmosis could be explained by poor antenatal screening
with delay in ﬁrst trimester screening in the study by Avelino
et al. This difference in rate of congenital toxoplasmosis when
comparing women with seroconversion with women with
suspected infection in pregnancy highlights the importance of
proper counselling of the parents and strategy of management of
the pregnancy according to the risk. To date, many studies are not
clear about case deﬁnition and tent to evaluate seroconversion
together with cases with suspected infection in pregnancy [23–
30]. A direct comparison between studies is rather difﬁcult,
because of different screening programs for toxoplasmosis,
different treatment schemes and risk groups analyzed.
The most important limitation of our study is the retrospective
approach. We do acknowledge that several biases may be
highlighted due to the study design. Women positive to toxoplas-
mosis in pregnancy could be not referred to our institution. Women
could be not screened during pregnancy. Only one fetus among those
with induced termination of pregnancy, miscarriage and stillbirth
cases was tested for toxoplasmosis infection. Pregnancy outcomes
were available for only 476 pregnancies.Conclusion
In conclusion, 50% of women referred for suspected toxoplas-
mosis during pregnancy were considered not infected in
pregnancy after appropriate analysis of serology. The incidence
of congenital toxoplasmosis was as low as 0.1 per 1000 live births.
The incidence of congenital toxoplasmosis was statistically
signiﬁcant higher in women with seroconversion compared to
those with suspected infection, respectively 32.9% (52/158) and
4.7% (15/321). These ﬁndings should question about beneﬁts and
cost-effectiveness of universal screening policy for toxoplasmosis
in pregnancy.
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